TECH240920C70000
- 3.80
- -1.90-33.33%
Bio-Techne Newsroom
Some Investors May Be Willing To Look Past Bio-Techne's (NASDAQ:TECH) Soft Earnings
Baird Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $82
Optimistic Growth and Improved Financial Outlook for Bio-Techne: A Buy Recommendation
ScaleReady Announces the Inaugural G-Rex Grant Has Been Awarded to Stanford Medicine Laboratory for Cell and Gene Medicine
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH)
Bio-Techne | 10-K: FY2024 Annual Report
Is Wall Street Bullish or Bearish on Bio-Techne Stock?
Scotiabank Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $83
Scotiabank Reaffirms Their Buy Rating on Bio-Techne (TECH)
Bio-Techne To Go Ex-Dividend On August 19th, 2024 With 0.08 USD Dividend Per Share
Benchmark Co. Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $95
Benchmark Co. Remains a Buy on Bio-Techne (TECH)
Bio-techne Insider Sold Shares Worth $1,153,664, According to a Recent SEC Filing
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Bio-Techne Corporation Just Missed EPS By 6.1%: Here's What Analysts Think Will Happen Next
Bio-Techne: A Compelling Buy Amidst Market Uncertainty and Anticipated Growth Catalysts
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Pediatrix Medical Group (MD) and Arcus Biosciences (RCUS)